Last reviewed · How we verify
CL-108
CL-108 is a novel, orally administered, non-opioid, non-sedating, and non-addictive analgesic.
CL-108 is a novel, orally administered, non-opioid, non-sedating, and non-addictive analgesic. Used for Acute pain, Chronic pain.
At a glance
| Generic name | CL-108 |
|---|---|
| Also known as | Low-dose CL-108 and High-dose CL-108 |
| Sponsor | Charleston Laboratories, Inc |
| Drug class | TRPM8 receptor antagonist |
| Target | TRPM8 |
| Modality | Small molecule |
| Therapeutic area | Pain management |
| Phase | Phase 3 |
Mechanism of action
CL-108 works by targeting and inhibiting the TRPM8 receptor, which is involved in the transmission of pain signals. This inhibition leads to a reduction in pain perception without the side effects associated with traditional opioids.
Approved indications
- Acute pain
- Chronic pain
Common side effects
- Nausea
- Headache
- Dizziness
Key clinical trials
- Safety Follow-up Study of Participants Dosed With INV-347 in Study INV-CL-108 (PHASE1)
- A Controlled Study to Determine the Efficacy and Safety of CL-108 5 mg for Acute Pain and the Prevention of OINV (PHASE3)
- A Study in Opioid-Experienced, Non-Dependent Recreational Drug Users to Determine the Abuse Potential and Safety of CL-108 Tablets Administered Via the Oral Route (PHASE1)
- A Four-Period, Four-Treatment, Four-Way Relative Bioavailability Study of CL-108 Under Fed and Fasted Conditions (PHASE1)
- A Multi-Center Actual-Use Study on the Safety of CL 108 for the Treatment of Moderate to Severe Acute Pain Associated With Osteoarthritis of the Knee or Hip (PHASE3)
- Phase III Study of the Safety and Efficacy of Cl-108 in the Treatment of Moderate to Severe Pain (PHASE3)
- A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Acute Pain and Opioid-Induced Nausea and Vomiting (OINV) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CL-108 CI brief — competitive landscape report
- CL-108 updates RSS · CI watch RSS
- Charleston Laboratories, Inc portfolio CI